Table 4.
Univariable and multifactorial analysis for progression-free survival (N = 36).
| Variable | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (years) | 0.709 | |||
| ≤50 | Reference | |||
| >50 | 0.803 (0.264–2.441) | |||
| ECOG | 0.125 | |||
| 1 | Reference | |||
| 0 | 0.370 (0.061–2.253) | |||
| Gender | 0.592 | |||
| Male | Reference | |||
| Female | 0.743 (0.235–2.352) | |||
| Lesion site | ||||
| Upper 1/3 | Reference | |||
| Middle 1/3 | 0.792 (0.123–2.345) | 0.283 | ||
| Lower 1/3 | 0.526 (0.067–2.545) | 0.326 | ||
| Pre-BMI(Kg/m2) | 0.563 | |||
| Underweight (<18.5) | Reference | |||
| Normal (≥18.5) | 0.554 (0.112–2.750) | |||
| Post-BMI(Kg/m2) | 0.703 | |||
| Underweight (<18.5) | Reference | |||
| Normal (≥18.5) | 0.749 (0.193–2.910) | |||
| Borrmann type | 0.410 | |||
| III–IV | Reference | |||
| I–II | 0.619 (0.166–2.301) | |||
| Histological | 0.471 | |||
| Low | Reference | |||
| High-moderate | 0.643 (0.148–2.797) | |||
| cT staging | 0.823 | |||
| T4 | Reference | |||
| T3 | 0.844 (0.206–3.462) | |||
| cN staging | 0.776 | |||
| N3 | Reference | |||
| N1–N2 | 0.832 (0.247–2.802) | |||
| Lesion size(cm) | 0.918 | |||
| ≥5 | Reference | |||
| <5 | 0.866 (0.261–2.870) | |||
| FCC | 0.000 | 0.012 | ||
| Negative | Reference | Reference | ||
| Positive | 6.155 (1.359–27.890) | 5.092 (2.112–17.809) | ||
| Sarcopenia | ||||
| Non-Sarcopenic | Reference | Reference | ||
| Pre-treatment Sarcopenia | 7.539 (1.354–41.980) | <0.0001 | 8.212 (1.569–36.582) | 0.001 |
| Newly developed Sarcopenia | 2.939 (1.464-18.630) | 0.019 | 3.084 (1.042-14.236) | 0.013 |
| ΔSMI (%)/50 days | 0.000 | 0.002 | ||
| No-SML | Reference | Reference | ||
| SML | 11.710 (2.078–66.030) | 9.562 (2.341–38.092) | ||
ECOG, Eastern Cooperative Oncology Group; SML, Significant muscle loss; FCC, Free cancer cells.